Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234832 · ClinicalTrials.gov registry record · Phase 3
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 10,777
- Enrollment target
NCT00234832 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 10,777 participants.
The verdict
NCT00234832, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,777 participants
- Enrollment target
Study Summary
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
Interventions
- DRUG Placebo
- DRUG Sibutramine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,777 participants |
| Start Date | 2003-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234832
The ClinicalTrials.gov registry entry for NCT00234832 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10,777 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00234832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234832 about?
NCT00234832 is a clinical study titled "A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients". The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
What is the current status of trial NCT00234832?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,777 participants. The study started on 2003-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00234832?
The interventions under investigation include: Placebo (DRUG), Sibutramine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00234832?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.